BACKGROUND: First-degree relatives of patients with breast or ovarian cancer have increased risks for these cancers. Little is known about how their risks vary with the patient's cancer site, carrier status for predisposing genetic mutations, or age at cancer diagnosis. METHODS: We evaluated breast and ovarian cancer incidence in 2,935 female first-degree relatives of non-Hispanic White female patients with incident invasive cancers of the breast (n = 669) or ovary (n = 339) who were recruited from a population-based cancer registry in northern California. Breast cancer patients were tested for BRCA1 and BRCA2 mutations. Ovarian cancer patients were tested for BRCA1 mutations. We estimated standardized incidence ratios (SIR) and 95% confidence intervals (95% CI) for breast and ovarian cancer among the relatives according to the patient's mutation status, cancer site, and age at cancer diagnosis. RESULTS: In families of patients who were negative or untested for BRCA1 or BRCA2 mutations, risks were elevated only for the patient's cancer site. The breast cancer SIR was 1.5 (95% CI, 1.2-1.8) for relatives of breast cancer patients, compared with 1.1 (95% CI, 0.8-1.6) for relatives of ovarian cancer patients (P = 0.12 for difference by patient's cancer site). The ovarian cancer SIR was 0.9 (95% CI, 0.5-1.4) for relatives of breast cancer patients, compared with 1.9 (95% CI, 1.0-4.0) for relatives of ovarian cancer patients (P = 0.04 for difference by site). In families of BRCA1-positive patients, relatives' risks also correlated with the patient's cancer site. The breast cancer SIR was 10.6 (95% CI, 5.2-21.6) for relatives of breast cancer patients, compared with 3.3 (95% CI, 1.4-7.3) for relatives of ovarian cancer patients (two-sided P = 0.02 for difference by site). The ovarian cancer SIR was 7.9 (95% CI, 1.2-53.0) for relatives of breast cancer patients, compared with 11.3 (3.6-35.9) for relatives of ovarian cancer patients (two-sided P = 0.37 for difference by site). Relatives' risks were independent of patients' ages at diagnosis, with one exception: In families ascertained through a breast cancer patient without BRCA mutations, breast cancer risks were higher if the patient had been diagnosed before age 40 years. CONCLUSION: In families of patients with and without BRCA1 mutations, breast and ovarian cancer risks correlate with the patient's cancer site. Moreover, in families of breast cancer patients without BRCA mutations, breast cancer risk depends on the patient's age at diagnosis. These patterns support the presence of genes that modify risk specific to cancer site, in both carriers and noncarriers of BRCA1 and BRCA2 mutations.
BACKGROUND: First-degree relatives of patients with breast or ovarian cancer have increased risks for these cancers. Little is known about how their risks vary with the patient's cancer site, carrier status for predisposing genetic mutations, or age at cancer diagnosis. METHODS: We evaluated breast and ovarian cancer incidence in 2,935 female first-degree relatives of non-Hispanic White female patients with incident invasive cancers of the breast (n = 669) or ovary (n = 339) who were recruited from a population-based cancer registry in northern California. Breast cancerpatients were tested for BRCA1 and BRCA2 mutations. Ovarian cancerpatients were tested for BRCA1 mutations. We estimated standardized incidence ratios (SIR) and 95% confidence intervals (95% CI) for breast and ovarian cancer among the relatives according to the patient's mutation status, cancer site, and age at cancer diagnosis. RESULTS: In families of patients who were negative or untested for BRCA1 or BRCA2 mutations, risks were elevated only for the patient's cancer site. The breast cancer SIR was 1.5 (95% CI, 1.2-1.8) for relatives of breast cancerpatients, compared with 1.1 (95% CI, 0.8-1.6) for relatives of ovarian cancerpatients (P = 0.12 for difference by patient's cancer site). The ovarian cancer SIR was 0.9 (95% CI, 0.5-1.4) for relatives of breast cancerpatients, compared with 1.9 (95% CI, 1.0-4.0) for relatives of ovarian cancerpatients (P = 0.04 for difference by site). In families of BRCA1-positive patients, relatives' risks also correlated with the patient's cancer site. The breast cancer SIR was 10.6 (95% CI, 5.2-21.6) for relatives of breast cancerpatients, compared with 3.3 (95% CI, 1.4-7.3) for relatives of ovarian cancerpatients (two-sided P = 0.02 for difference by site). The ovarian cancer SIR was 7.9 (95% CI, 1.2-53.0) for relatives of breast cancerpatients, compared with 11.3 (3.6-35.9) for relatives of ovarian cancerpatients (two-sided P = 0.37 for difference by site). Relatives' risks were independent of patients' ages at diagnosis, with one exception: In families ascertained through a breast cancerpatient without BRCA mutations, breast cancer risks were higher if the patient had been diagnosed before age 40 years. CONCLUSION: In families of patients with and without BRCA1 mutations, breast and ovarian cancer risks correlate with the patient's cancer site. Moreover, in families of breast cancerpatients without BRCA mutations, breast cancer risk depends on the patient's age at diagnosis. These patterns support the presence of genes that modify risk specific to cancer site, in both carriers and noncarriers of BRCA1 and BRCA2 mutations.
Authors: Kevin M Elias; S Intidhar Labidi-Galy; Allison F Vitonis; Jason L Hornick; Leona A Doyle; Michelle S Hirsch; Daniel W Cramer; Ronny Drapkin Journal: Gynecol Oncol Date: 2013-12-14 Impact factor: 5.482
Authors: Natalia Teixeira; Annemieke van der Hout; Jan C Oosterwijk; Janet R Vos; Peter Devilee; Klaartje van Engelen; Hanne Meijers-Heijboer; Rob B van der Luijt; Mieke Kriege; Arjen R Mensenkamp; Matti A Rookus; Kees E van Roozendaal; Marian J E Mourits; Geertruida H de Bock Journal: Eur J Hum Genet Date: 2018-02-26 Impact factor: 4.246
Authors: Susan L Neuhausen; Hilmi Ozcelik; Melissa C Southey; Esther M John; Andrew K Godwin; Wendy Chung; Jeniffer Iriondo-Perez; Alexander Miron; Regina M Santella; Alice Whittemore; Irene L Andrulis; Saundra S Buys; Mary B Daly; John L Hopper; Daniela Seminara; Ruby T Senie; Mary Beth Terry Journal: Breast Cancer Res Treat Date: 2008-08-14 Impact factor: 4.872
Authors: Timothy R Rebbeck; Nandita Mitra; Susan M Domchek; Fei Wan; Shannon Chuai; Tara M Friebel; Saarene Panossian; Amanda Spurdle; Georgia Chenevix-Trench; Christian F Singer; Georg Pfeiler; Susan L Neuhausen; Henry T Lynch; Judy E Garber; Jeffrey N Weitzel; Claudine Isaacs; Fergus Couch; Steven A Narod; Wendy S Rubinstein; Gail E Tomlinson; Patricia A Ganz; Olufunmilayo I Olopade; Nadine Tung; Joanne L Blum; Roger Greenberg; Katherine L Nathanson; Mary B Daly Journal: Cancer Res Date: 2009-07-07 Impact factor: 12.701
Authors: Linda S Cook; Harold E Nelson; Christine A Stidley; Yan Dong; Pamela J Round; Ernest K Amankwah; Anthony M Magliocco; Christine M Friedenreich Journal: Gynecol Oncol Date: 2013-04-28 Impact factor: 5.482
Authors: Habibul Ahsan; Jerry Halpern; Muhammad G Kibriya; Brandon L Pierce; Lin Tong; Eric Gamazon; Valerie McGuire; Anna Felberg; Jianxin Shi; Farzana Jasmine; Shantanu Roy; Rachelle Brutus; Maria Argos; Stephanie Melkonian; Jenny Chang-Claude; Irene Andrulis; John L Hopper; Esther M John; Kathi Malone; Giske Ursin; Marilie D Gammon; Duncan C Thomas; Daniela Seminara; Graham Casey; Julia A Knight; Melissa C Southey; Graham G Giles; Regina M Santella; Eunjung Lee; David Conti; David Duggan; Steve Gallinger; Robert Haile; Mark Jenkins; Noralane M Lindor; Polly Newcomb; Kyriaki Michailidou; Carmel Apicella; Daniel J Park; Julian Peto; Olivia Fletcher; Isabel dos Santos Silva; Mark Lathrop; David J Hunter; Stephen J Chanock; Alfons Meindl; Rita K Schmutzler; Bertram Müller-Myhsok; Magdalena Lochmann; Lars Beckmann; Rebecca Hein; Enes Makalic; Daniel F Schmidt; Quang Minh Bui; Jennifer Stone; Dieter Flesch-Janys; Norbert Dahmen; Heli Nevanlinna; Kristiina Aittomäki; Carl Blomqvist; Per Hall; Kamila Czene; Astrid Irwanto; Jianjun Liu; Nazneen Rahman; Clare Turnbull; Alison M Dunning; Paul Pharoah; Quinten Waisfisz; Hanne Meijers-Heijboer; Andre G Uitterlinden; Fernando Rivadeneira; Dan Nicolae; Douglas F Easton; Nancy J Cox; Alice S Whittemore Journal: Cancer Epidemiol Biomarkers Prev Date: 2014-02-03 Impact factor: 4.254
Authors: Gillian S Dite; Enes Makalic; Daniel F Schmidt; Graham G Giles; John L Hopper; Melissa C Southey Journal: Breast Cancer Res Date: 2012-08-28 Impact factor: 6.466